At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 26, 2026 at 07:30 ET
BrainsWay completed a $6 million milestone-based convertible loan to Neurolief following FDA approval of Neurolief's Proliv™Rx system for treatment-resistant depression. The investment expands BrainsWay's strategic reach into at-home neurostimulation, complementing its in-clinic Deep TMS™ technology, with potential for further funding and an option to acquire Neurolief outright.
- BrainsWay disbursed an additional $6 million convertible loan to Neurolief, triggered by FDA PMA approval of Proliv™Rx for MDD.
- Total investment in Neurolief now stands at $11 million, with a potential additional $5 million equity tranche tied to revenue performance.
- BrainsWay holds a call option to acquire all of Neurolief based on enterprise value or revenue multiple, depending on exercise timing.
- Neurolief’s Proliv™Rx is the first FDA-approved at-home neurostimulation device for treatment-resistant depression.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access